Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sionna Therapeutics (SION) Net Income (2024 - 2026)

Quarterly results put Net Income at -$26.8 million for Q1 2026, down 60.75% from a year ago — trailing twelve months through Mar 2026 was -$85.8 million (down 28.01% YoY), and the annual figure for FY2025 was -$75.7 million, down 21.32%.

Sionna Therapeutics has reported Net Income over the past 3 years, most recently at -$26.8 million for Q1 2026.

  • Net Income reached -$26.8 million in Q1 2026 per SION's latest filing, down from -$20.4 million in the prior quarter.
  • Across five years, Net Income topped out at -$8.7 million in Q2 2024 and bottomed at -$26.8 million in Q1 2026.
  • Median Net Income over the past 3 years was -$18.2 million (2025), compared with a mean of -$18.3 million.
  • Peak annual rise in Net Income hit 20.61% in 2025, while the deepest fall reached 109.02% in 2025.
  • Over 3 years, Net Income stood at -$16.0 million in 2024, then fell by 27.64% to -$20.4 million in 2025, then tumbled by 31.01% to -$26.8 million in 2026.
  • Business Quant data shows Net Income for SION at -$26.8 million in Q1 2026, -$20.4 million in Q4 2025, and -$20.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -2.99 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -8.50 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -14.46 Mn
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 1.03 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 727.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -3.40 Mn
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 205.99 Mn
10 Sionna Therapeutics 1.87 Bn 1.87 Bn - -26.78 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -26.78 Mn
Dec 31, 2025 -20.44 Mn
Sep 30, 2025 -20.35 Mn
Jun 30, 2025 -18.24 Mn
Mar 31, 2025 -16.66 Mn
Dec 31, 2024 -16.01 Mn
Sep 30, 2024 -25.63 Mn
Jun 30, 2024 -8.73 Mn
Mar 31, 2024 -12.02 Mn